Actualizado 10/07/2012 03:32
- Comunicado -

Eisai Announces Preliminary Results of Phase III Study of Halaven® (Eribulin) in Locally Advanced or Metastatic Breast C

For further information please visit our web site http://www.eisai.com

July 2012 / Halaven-UK0012

References

1. Halaven (eribulin) SPC available from: http://www.medicines.org.uk/EMC/medicine... (Updated May 2012)

2. Xeloda (capecitabine) SPC available from: http://www.medicines.org.uk/EMC/medicine... /

3. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet. 2011; 377: 914 -923

4. Cardoso, M. and Castiglione F. Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. On behalf of the ESMO Guidelines Working Group. Ann Oncol (2009) 20 (suppl 4): iv15-iv18

CONTACT: Media Enquiries: Eisai Europe Ltd, Charlotte Andrews / CressidaRobson, +44-(0)7947-231513 / +44-(0)790-831-4155 ,Charlotte_andrews@eisai.net / Cressida_robson@eisai.net . Tonic LifeCommunications: Benjamyn Tan / Leah Peyton, +44-(0)207-798-9262 /,+44-(0)7788-191434, benjamyn.tan@toniclc.com, eisaioncology@toniclc.com

Contenido patrocinado